The financing of the drug Kaftrio , whose active ingredients are ivacaftor, tezacaftor and elexacaftor, has been included within the National Health System after the agreement reached by consensus in the Interministerial Commission on Drug Prices held last October.
In addition, the Ministry emphasizes that this triple therapy will finally be financed in a combined administration regimen with 150 mg tablets of ivacaftor for the treatment of cystic fibrosis in patients 12 years of age or older with at least one F508del mutation in the gene. cystic fibrosis transmembrane conductance regulator (CFTR), which includes the April 2021 extension of the indication initially authorized by the European Medicines Agency.
Spain joins the European Union countries such as France, Austria, Czech Republic, Italy, United Kingdom, Ireland, Denmark, Finland, Switzerland, Luxembourg or Slovenia that finance this treatment after the approval of the drug by the European Agency of the Medicine.
Health hopes that the benefits of this treatment will make it possible for people affected by cystic fibrosis to improve both their quality and life expectancy for these patients.